NAS:SGEN (USA) Also Trade In: Germany

Seattle Genetics Inc $ 175.66 -0.96 (-0.54%)

Avg Vol (1m):
Market Cap $:
30.56 Bil
Enterprise Value $:
29.73 Bil
P/E (TTM):
Warning! GuruFocus has detected 1 Severe warning sign with SGEN. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

SGEN News and Headlines - Seattle Genetics Inc

GuruFocus Articles Total 27
  • 1
  • 2

Biotech's shares up more than 140% in past year

Even though it’s not expected to be profitable until 2022, Seattle Genetics Inc. (SGEN) continues to generate strong investor backing. Shares of the 27-year-old Bothell, Washington-based biotech have shot up more than 140% in the past year.

The stock climbed about $15 this week alone as the company beat earnings estimates and reported sterling sales of the new bladder cancer treatment Padcev, which the company co-developed with Astellas Pharma Inc. (TSE:4503) of Japan

Padcev just received approval in mid-December. Yet, in the first quarter, the newcomer recorded sales of more than $34 million. FiercePharma reported that number surprised JPMorgan analyst

80 Views    Barry Cohen    2020-05-07 20:42
Needham analyst raises target price after promising results of drug trial

Seattle Genetics Inc. (SGEN) CEO Clay Siegall called new data from the study of the company’s breast cancer drug “stunning.” Based on the fresh information, Needham analyst Chad Messer raised his target price on Seattle Genetics by $9 to $130, according to an article in The Fly.

Messner’s expectations are in line with the 16 analysts offering 12-month price forecasts for the biotech company. They have a median target of $120, with a high estimate of $140 and a low estimate of $87. Seattle Genetics, currently trading at just over $112, is rated a buy.

The release of

138 Views    Barry Cohen    2019-12-12 21:57
Cancer treatments draw plenty of investor interest. Here are the top 5 oncology companies that I believe offer investors the largest opportunities

Cancer is a devastating ailment. While the oncology field has progressed in leaps and bounds over the past couple of decades, there are still many cancer types that come with few solutions and high mortality rates.

The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. By the year 2026, it is expected that the oncology market will be worth $126.9 billion. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy

302 Views    Joshua Rodriguez    2019-04-10 16:40
Competitive advantages are dynamic and can be positive, negative or stable

For some of us, corporate moats are static. But for the moat team at Morningstar (MORN), they are dynamic.

In the book “Why Moats Matter: The Morningstar Approach to Stock Investing,” contributor Stephen Ellis, the head of financial services equity research at Morningstar, wrote, “Moat ratings can tell you the width of a company’s current moat, but trend ratings tell you if that moat is holding up well, is getting even stronger, or is in danger of being filled in by a rampaging horde of invaders.”

Ellis, along with lead authors Heather Brilliant and Elizabeth Collins, argue that as corporations

354 Views    Robert Abbott    2019-03-27 21:54
The failure of ImmunoGen's antibody-drug conjugate in Phase III trials this week has investors wondering whether this particular approach to cancer treatment is viable long term

Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies.

The stock fell 50% on the news, but there may be wider implications here than a hit to a single company. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.

That statement isn’t coming from a scientific perspective, but from an investment and economic

129 Views    Matt Winkler    2019-03-06 17:22
Seattle Genetics tops the list

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors.

Eight gurus are invested in Seattle Genetics Inc. (SGEN). The biotech company develops therapies for the treatment of cancer. It has a market cap of $12.41 billion. Its revenue of $575.66 million has climbed 26.40% over a 10-year period.

The stock is trading with a price-book ratio of 8.97. As of Friday, the price of $78 is 2.25% below its 52-week high and 61.34% above its 52-week low. Over the last 10 years, it has returned a gain of 551%.

The company’s largest

118 Views    Tiziano Frateschi    2018-09-17 20:26
Guru real-time pick highlight

Baupost Group manager Seth Klarman (Trades, Portfolio) disclosed on Monday that he increased his stake in Atara Biotherapeutics Inc. (ATRA).

Trade details

Klarman invested in 895,000 shares of Atara for $39 per share. With this transaction, the manager expanded the portfolio 0.35%.


According to GuruFocus estimates, Klarman gained approximately 28% on the stock.


Company background

San Francisco-based Atara develops novel treatments for patients with cancer, autoimmune and viral diseases. GuruFocus ranks Atara’s financial strength 8 out of 10 as the company has

294 Views    James Li    2018-04-10 16:38
Seattle Genetics rises in premarket trading

The U.S. stock market indexes opened in green Monday. The S&P 500, the Nasdaq and the Dow Jones started the week with gains.

Shares of Seattle Genetics Inc. (SGEN) traded more than 5% higher on the back of the company's announcement the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Adcetris (brentuximab vedotin) in combinationn with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. In June, the company announced positive results for the phase III ECHELON-1 clinical trial. The results of the full study will be announced at the American Society of

69 Views    Omar Venerio    2017-10-02 18:03
These stocks had great 12-month performances

According to GuruFocus' All-in-One Guru Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter.

ONEOK Partners LP (OKS) with a market cap of $14.88 billion has outperformed the S&P500 Index by 88.5% over the last 12 months.

ONEOK is engaged in the gathering, processing, storage and transportation of natural gas in the United States.

Its shares are trading with a price-book (P/B) ratio of 2.48. According to the DCF calculator, the company looks overpriced by 280% at

423 Views    Tiziano Frateschi    2017-02-21 21:01
The largest insiders' buys and sales of the week

The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$200,000+” duration to October 2016 and November 2016 and All Insider Sales to “$5,000,000+”.

According to the above filters, the following are recent buys and sells from company insiders in the past week.

Carl Icahn (Trades, Portfolio), 10% owner of Herbalife Ltd. (HLF), bought 1,832,402 shares for $54.70 per share on Nov. 3. Since then, the stock price has

1450 Views    Tiziano Frateschi    2016-11-05 15:20
Insiders buying the biggest bundles of their companies' stock

The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to

731 Views    Tiziano Frateschi    2016-03-18 21:00
Warren Buffett adds to holding in Phillips 66

The All-in-One Screener can be used to find insider buys and sales over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "February 2016."

According to the above filters, the following are the recent buys from company insiders in the past week.

On Feb. 12 and 18, Energy Capital Partners a director and 10% owner of Summit Midstream Partners LP (SMLP), bought 436,394 shares of the company at the price of $15.23 per share. Since then, the price of the stock has risen by 4.4%

1790 Views    Tiziano Frateschi    2016-02-19 22:36
Roundup of recent insider buys from the past week

The All-In-One Guru Screener can be used to find insider buys over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "September 2015."

According to the above filters, the following are the recent buys from company insiders during the second week of September.

On Sept. 10, Baker Bros. Advisors LP., which now holds more than 10% of outstanding shares of Aquinox Pharmaceuticals Inc. (AQXP) bought 2,480,032 shares of the company at the average price of $15.50 per share with a total cost of $38,440,500. Since

1809 Views    Tiziano Frateschi    2015-09-18 21:43

As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) invests almost exclusively in health care companies. It’s been a successful investment niche. Vanguard enjoyed returns exceeding 28% in 2014, 43% in 2013 and 15% in 2012.

Vanguard bought added two new stakes to its portfolio in the second quarter – Baxter International Inc. (BAX) and Seattle Genetics Inc. (SGEN).

Vanguard purchased 1,945,220 shares of Baxter International, an Illinois-based medical equipment company, for an average price of $37.39 per share. The transaction had a 0.15% impact on Vanguard’s portfolio.

Baxter International has a market cap of $22.86

1682 Views    David Goodloe    2015-08-06 21:14

The All-In-One Guru Screenercan be used to find out the most insider buys over the last week by clicking on the insiders tab and changing the settings for All Insider Buying

628 Views    Tiziano Frateschi    2015-05-22 20:46

The All-In-One Guru Screener can be used to find out the most insider buys over the last week by clicking on the insiders tab and changing the settings for All Insider Buying and Duration to "over the past 7 days."

On May 8, Alibaba Group Holding Ltd which is 10% owner of Zulily Inc (ZU) paid $56,161,000 to buy 4,812,425 shares of ZU at an average price of $11.67. After that trade, the price of ZU rose by 14% and reached $13.30.

ZU is now trading at a very high P/E ratio of 117.70 even

1097 Views    Tiziano Frateschi    2015-05-12 21:55

Biotechnology products are identified to be 21% of the aggregate $714bn worldwide business sector for physician endorsed medications in 2012, comparing to $150bn of sales. The measure of the physician endorsed medications business sector is required to develop at a CAGR of 3.8% to arrive at $895bn in 2018, and the biotechnology industry’s share of this is anticipated to grow to 25%, equivalent to $224bn.This speaks to a CAGR of 6.9% for the biotech market, higher than the development of total pharmaceutical industry in light of the fact that biotechnology items have a less forceful rate of offers disintegration from

615 Views    amal.singh70    2014-10-28 18:50

ImmunoGen, Inc. (?IMGN) will announce its fourth-quarter earnings and hold its annual fiscal year financial conference before the market opens on Friday, Aug. 1, 2014, at 8:00 a.m. EDT. You can access the live broadcast from the Investor Information site on the company website at Alternatively, you can attend the live conference via telephone by calling 1-913-905-3226 and entering the conference ID number 2600176.

ImmunoGen develops drugs to treat different types of cancer. The company uses its ADC technology, or antibody-drug conjugate, to directly target a specific type of tumor without harming healthy cells.

Analysts Expect:

  • EPS ranging
663 Views    Karen Rogers    2014-07-30 22:21
According to [url=]GuruFocus Insider Data[/url], the largest CFO sells during the past week were: U.S. Bancorp, Seattle Genetics Inc, Cardinal Health Inc, Alexion Pharmaceuticals Inc, and Abiomed Inc. [b]U.S. Bancorp (USB): Vice Chairman and CFO Andrew Cecere Sold 259,355 Shares[/b] Vice Chairman and CFO [url=]Andrew Cecere[/url] sold 259,355 shares of USB stock on July 18 at the average price of $37.02. Andrew Cecere owns at least 238,032 shares after this. The price of the stock has increased by 0.65% since. U.S. Bancorp was incorporated in Delaware in 1929. It is a multi-state financial services holding company headquartered in Minneapolis, Minnesota.
950 Views    Jimmy Xiao    2013-07-21 13:21
According to [url=]GuruFocus Insider Data[/url], the largest CFO sells during the past week were: Seattle Genetics Inc., Profire Energy Inc., Marriott International Inc, Express Scripts Holdings Company, Lionbridge Technologies Inc. and Repligen Corporation. [b] Seattle Genetics Inc. (SGEN): CFO Todd E. Simpson Sold 95,000 Shares[/b] CFO Todd E. Simpson sold 95,000 shares of SGEN stock on 09/06/2012 at the average price of $28.5. Todd E. Simpson owns at least 70,762 shares after this. The price of the stock has increased by 1.37% since. Seattle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Seattle Genetics Inc. has a
492 Views    Jimmy Xiao    2012-09-10 14:12

Headlines Total 77
  • 1

2020-09-16 $ 176.62 (1%)
2020-09-15 $ 174.87 (1.79%)
2020-09-14 $ 171.79 (14.55%)
2020-09-03 $ 156.07 (1.57%)
2020-08-28 $ 153.66 (-0.29%)
2020-08-13 $ 160.14 (0.85%)
2020-08-06 $ 162.59 (-1.5%)
2020-07-31 $ 166.27 (-2.85%)
2020-07-30 $ 171.14 (1.62%)
2020-07-23 $ 172.9 (-2.22%)
2020-07-10 $ 174.35 (-3.76%)
2020-07-06 $ 170.45 (0.84%)
2020-07-03 $ 169.03 (%)
2020-06-23 $ 170.92 (0.59%)
2020-06-22 $ 170.92 (0.59%)
2020-06-10 $ 156.7 (5.21%)
2020-05-15 $ 160.33 (0.15%)
2020-05-14 $ 160.09 (1.43%)
2020-05-13 $ 157.84 (-2.43%)
2020-05-12 $ 161.77 (0.5%)
2020-05-11 $ 160.96 (2.09%)
2020-05-09 $ 157.67 (-3.42%)
2020-05-08 $ 157.67 (-3.42%)
2020-05-07 $ 163.26 (-0.84%)
2020-05-06 $ 164.64 (-0.48%)
2020-05-04 $ 155.76 (6.95%)
2020-05-01 $ 145.64 (6.13%)
2020-04-30 $ 137.23 (-0.62%)
2020-04-29 $ 138.08 (-3.69%)
2020-04-28 $ 143.37 (-2.79%)
2020-04-23 $ 140.88 (1.34%)
2020-04-20 $ 142.55 (4.15%)
2020-04-11 $ 120.32 (%)
2020-04-03 $ 116.51 (-1.82%)
2020-03-11 $ 104.51 (-2.73%)
2020-02-12 $ 118.07 (0.1%)
2020-01-11 $ 112.44 (0.55%)
2019-12-12 $ 112.26 (0.83%)
2019-12-11 $ 113.98 (-0.13%)
2019-11-13 $ 110.64 (2.16%)
2019-10-10 $ 81.55 (1.98%)
2019-10-02 $ 84.54 (-1.7%)
2019-04-10 $ 80.91 (1.9%)
2015-05-22 $ 43.23 (-1.21%)
2014-10-28 $ 36.37 (2.77%)
2012-09-10 $ 28.25 (-2.22%)
2011-03-19 $ 14.28 (2.37%)
2010-11-05 $ 14.71 (-0.81%)
2010-08-06 $ 12.27 (0.57%)
2010-05-07 $ 10.61 (-8.22%)
2009-08-10 $ 11.84 (0.34%)
2009-05-09 $ 8.67 (5.86%)
Total 77
  • 1